Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., operates as a biotechnology company in the United States.
Imperfect balance sheet and overvalued.
Share Price & News
How has Advanced Proteome Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: APC's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: APC underperformed the Canadian Biotechs industry which returned 17.7% over the past year.
Return vs Market: APC underperformed the Canadian Market which returned -11.3% over the past year.
Price Volatility Vs. Market
How volatile is Advanced Proteome Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StInsider Buying: Alexander Krantz Just Spent US$66k On Advanced Proteome Therapeutics Corporation (CVE:APC) Shares
2 months ago | Simply Wall StShould You Be Concerned About Advanced Proteome Therapeutics Corporation's (CVE:APC) Historical Volatility?
6 months ago | Simply Wall StWhat You Must Know About Advanced Proteome Therapeutics Corporation's (CVE:APC) Beta Value
Is Advanced Proteome Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate APC's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate APC's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: APC is unprofitable, so we can't compare its PE Ratio to the XN Biotechs industry average.
PE vs Market: APC is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate APC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: APC is good value based on its PB Ratio (3.3x) compared to the CA Biotechs industry average (4.2x).
How is Advanced Proteome Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Advanced Proteome Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Take a look at our analysis of APC’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- Advanced Proteome Therapeutics competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Advanced Proteome Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: APC is currently unprofitable.
Growing Profit Margin: APC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: APC is unprofitable, but has reduced losses over the past 5 years at a rate of 13.3% per year.
Accelerating Growth: Unable to compare APC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: APC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).
Return on Equity
High ROE: APC's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is Advanced Proteome Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: APC has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: APC has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: APC has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: APC's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: APC has sufficient cash runway for 1 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: APC is forecast to have sufficient cash runway for 1 months based on free cash flow estimates, but has since raised additional capital.
What is Advanced Proteome Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate APC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate APC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if APC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if APC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of APC's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Paul John Woodward (58yo)
Mr. Paul John Courtney Woodward serves as President, Chief Executive Officer and Director at Aether Catalyst Solutions, Inc. since July 2014. Mr. Woodward serves as the President and Director of Conation C ...
CEO Compensation Analysis
Compensation vs Market: Paul John's total compensation ($USD82.06K) is below average for companies of similar size in the Canadian market ($USD175.28K).
Compensation vs Earnings: Paul John's compensation has increased whilst the company is unprofitable.
|Chief Financial Officer||11.33yrs||US$24.76k||0.37% $13.0k|
|Secretary & Director||1.58yrs||US$15.06k||1.1% $38.6k|
Experienced Management: APC's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
|Secretary & Director||1.58yrs||US$15.06k||1.1% $38.6k|
|Member of Corporate Advisory Board||5.33yrs||no data||no data|
|Independent Director||1.58yrs||no data||0.59% $20.7k|
|Director||2.08yrs||no data||no data|
|Member of Scientific Advisory Board||2.5yrs||no data||no data|
|Member of Scientific Advisory Board||2.17yrs||no data||no data|
|Director||2.33yrs||no data||no data|
Experienced Board: APC's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: APC insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 28.4%.
Advanced Proteome Therapeutics Corporation's company bio, employee growth, exchange listings and data sources
- Name: Advanced Proteome Therapeutics Corporation
- Ticker: APC
- Exchange: TSXV
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$3.505m
- Shares outstanding: 26.96m
- Website: https://www.advancedproteome.com
- Advanced Proteome Therapeutics Corporation
- 650 Albany Street
- Suite 109
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|APTC.F||OTCPK (Pink Sheets LLC)||Yes||Common Shares||US||USD||Sep 1989|
|APC||TSXV (TSX Venture Exchange)||Yes||Common Shares||CA||CAD||Sep 1989|
|0||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Sep 1989|
|0||BST (Boerse-Stuttgart)||Yes||Common Shares||DE||EUR||Sep 1989|
|0||MUN (Boerse Muenchen)||Yes||Common Shares||DE||EUR||Sep 1989|
Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., operates as a biotechnology company in the United States. The company develops and commercializes a platform that is intended for the chemical modification of protein therapeutics, primarily antibody-drug conjugates. Its proprietary technology targets delivery of anti-cancer drugs to cancerous tumors. The company is headquartered in Boston, Massachusetts.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/07/14 00:20|
|End of Day Share Price||2020/07/13 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.